


1. PRODUCT AND COMPANY INFORMATION

Distributed By: WG Critical Care, LLC.
120 Route 17 North
Suite 115
Paramus, NJ 07652 USA

Product Name: **Ceftriaxone for Injection, USP**
Active Ingredient/Primary Component: Ceftriaxone for Injection, USP

Structure:



Chemical Name: (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, disodium salt, [6R-[6a,7b(Z)]]-, hydrate (2:7); (2) (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-*as*-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7²-(Z)-(O-methyloxime), disodium salt, sesquaterhydrate

Molecular Formula: C₁₈H₁₆N₈Na₂O₇S₃ · 3½H₂O
UNII Code: UNII-023Z5BR09K
CAS Number: 104376-79-6
Chemical Family: Antibacterial
Product Use: Pharmaceutical
Product Type: Prescription Drug
Container Information: Vials
Customer Service Phone Number: +1-888-493-0861
Emergency Phone Number: +1-866-562-4708 (Prosar)

WG Critical Care, LLC.

Ceftriaxone for Injection, USP	Safety Data Sheet (SDS)
Version: 3.3	Issue Date: 16 July 2015
	Page 1 of 6



2. HAZARDS IDENTIFICATION

PRIMARY PHYSICAL AND HEALTH HAZARDS: May cause irritations to the skin and eyes. May cause allergic reactions.

ROUTES OF ENTRY: Skin. Inhalation, Ingestion. Eye.

SIGNS & SYMPTOMS OF EXPOSURE: Acute signs and symptoms of exposure may include eye, skin, and respiratory irritation. May cause nausea, vomiting, abdominal pain, headache, dizziness, light headedness, or skin rash.

CHEMICAL LISTED AS CARCINOGEN: **NTP:** NO **IARC:** NO **OSHA:** NO

3. COMPOSITION / INFORMATION ON INGREDIENTS

<u>Ingredient</u>	<u>Weight %</u>	<u>CAS No.</u>
Ceftriaxone Sodium	100	104376-79-6

4. FIRST AID MEASURES

EYE EXPOSURE: Flush eyes with water for 10-20 minutes. Seek medical attention.

SKIN EXPOSURE: Remove contaminated clothing wash skin for 15-20 minutes with soap and water. Seek medical attention.

INGESTION: Do NOT induce vomiting. Flush mouth with water and seek medical attention immediately.

INHALATION: If there is breathing difficulty, remove from exposure and administer oxygen. See medical attention immediately.

NOTE TO PHYSICIAN: See patient package insert in shipping carton for complete information.

WG Critical Care, LLC.

Ceftriaxone for Injection, USP	Safety Data Sheet (SDS)
Version: 3.3	Issue Date: 16 July 2015
	Page 2 of 6



5. FIRE FIGHTING MEASURES

FLASH POINT:	Not Established
AUTO-IGNITION TEMPERATURE:	Not Established
FLAMMABLE LIMITS IN AIR:	Not Established
FLAMMABLE LIMITS:	Not Established
EXTINGUISHING MEDIA:	Water Spray, carbon dioxide, dry powder. Do not use a heavy stream of water.
UNUSUAL FIRE / EXPLOSION HAZARDS:	When heated to decomposition material, it emits toxic fumes: carbon monoxide, carbon dioxide, nitrogen oxides, sulfur compounds.

6. ACCIDENTAL RELEASE MEASURE

SPILL:	Contain and collect spillage and place in container for disposal according to local regulations (See Section 13). Wipe surface area clean with soap and water. Avoid contact with strong oxidizing agents.
RELEASE TO AIR:	Prevent release to environment. If aerosolized reduce exposure by ventilating area.
RELEASE TO WATER:	Refer to local water authority. Drain disposal is not recommended; refer to local, state, and federal disposal guidelines.

7. HANDLING AND STORAGE

GENERAL HANDLING:	When handling pharmaceutical products, avoid all contact and inhalation of dust, fumes, mist, and/or vapors associated with the product. Keep away from sources of ignition.
STORAGE CONDITIONS:	Keep containers tightly closed in a cool, well-ventilated place. Store at room temperature between 20°C and 25°C (68°F and 77°F).

WG Critical Care, LLC.

Ceftriaxone for Injection, USP	Safety Data Sheet (SDS)	
Version: 3.3	Issue Date: 16 July 2015	Page 3 of 6



8. EXPOSURE CONTROLS / PERSONAL PROTECTION

RESPIRATORY PROTECTION:	If aerosols are generated, a disposable dust/mist respirator (N95) may be used. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR 1910.134.
EYE PROTECTION:	Chemical goggles and/or face shield. Safety glasses are always required.
VENTILATION	Laboratory fume hood or local exhaust ventilation.
SKIN PROTECTION:	Work uniform or laboratory coat.
OTHER PROTECTIVE EQUIPMENT:	Protective Latex or Nitrile gloves
ADDITIONAL EXPOSURE PRECAUTIONS:	In production settings, airline-supplied, hood-type respirators are preferred. Shower and change clothing if skin contact occurs.

9. PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE:	Solid	SPECIFIC GRAVITY:	Not Established
APPEARANCE AND ODOR:	White to yellowish orange / N.D.	EVAPORATION RATE:	Not established
BOILING POINT:	Not established	MELTING POINT:	>155°C (decomposes)
VAPOR PRESSURE:	Not established	SOLUBILITY IN WATER:	Freely soluble
VAPOR DENSITY:	Not established	pH:	6.0-8.0

10. STABILITY AND REACTIVITY

STABILITY:	Keep containers tightly closed in a cool, well-ventilated place. Store at room temperature between 20°C and 25°C (68°F and 77°F).
INCOMPATIBILITY : (MATERIALS TO AVOID)	Strong oxidizing agents
HAZARDOUS POLYMERIZATION:	Will not occur
HAZARDOUS DECOMPOSITION:	When heated to decomposition material, it emits toxic fumes: carbon monoxide, carbon dioxide, nitrogen oxides, sulfur compounds. Avoid exposure to light, heat and strong oxidizing agents.
CONDITIONS TO AVOID:	

WG Critical Care, LLC.

Ceftriaxone for Injection, USP	Safety Data Sheet (SDS)	
Version: 3.3	Issue Date: 16 July 2015	Page 4 of 6



11. TOXICOLOGICAL INFORMATION

ACUTE TOXICITY

COMPONENT	TYPE	ROUTE	SPECIES	DOSAGE
Ceftriaxone Sodium	LD ₅₀	Oral	Mouse	> 10g/kg
Ceftriaxone Sodium	LD ₅₀	Oral	Rat	>10g/kg
Ceftriaxone Sodium	LD ₅₀	Intravenous	Mouse	2.8g/kg
Ceftriaxone Sodium	LD ₅₀	Intravenous	Rat	2g/kg
Ceftriaxone Sodium	LD ₅₀	Intravenous	Rabbit	240mg/kg

12. ECOLOGICAL INFORMATION

No applicable information found.

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL: Waste disposal must be in accordance with appropriate Federal, State, and local regulations.

14. TRANSPORT INFORMATION

REGULATORY ORGANIZATIONS:

DOT: Not Regulated

ICAO / IATA: Not Regulated

15. REGULATORY INFORMATION

Below is selected regulatory information chosen primarily for possible WG Critical Care use. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your city / state / country.

US Regulations

TSCA – No

CERCLA-No

SARA 302 – No

SARA 313 – No

OSHA Substance Specific - No

IMO: Not Regulated

WG Critical Care, LLC.

Ceftriaxone for Injection, USP	Safety Data Sheet (SDS)		
Version: 3.3	Issue Date: 16 July 2015	Page 5 of 6	



16. OTHER INFORMATION

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

WG Critical Care, LLC.

Ceftriaxone for Injection, USP	Safety Data Sheet (SDS)	
Version: 3.3	Issue Date: 16 July 2015	Page 6 of 6